Provention bio announces extension of fda user fee goal date for teplizumab to november 17, 2022

Red bank, n.j. , june 30, 2022 /prnewswire/ -- provention bio, inc. (nasdaq: prvb) (the "company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the u.s. food and drug administration (fda) has extended its review period by three months for the biologics license application (bla) for teplizumab.
PRVB Ratings Summary
PRVB Quant Ranking